U.S. biotech company Genzyme Inc. (GENZ) rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA (SNY) on Monday, setting the stage for a protracted and potentially hostile takeover battle. – Reuters
Risk Our Money Not Yours | Get 50% Off Any Account
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply